Among significant research news last week, US CNS specialist Axsome Therapeutics released new Phase III data on its recently ...

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Eli Lilly (NYSE:LLY) shares soar, driven by strong growth in weight-loss drugs, major investments, and bullish analyst ratings.

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Eli Lilly (LLY) stock in focus as company boosts U.S. medicine production investment to $50B, creating 3,000 skilled jobs & 10,000 construction roles. Read more here.

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Onvo Stock- Organovo's stock jumps 200% after Eli Lilly acquires its FXR program, including the promising IBD treatment ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

Organovo today announced that Eli Lilly and Company (NYSE:LLY) ("Lilly") will acquire Organovo's FXR program, including its ...

Eli Lilly (LLY) on Tuesday launched higher doses of Zepbound, or tirzepatide, in single-dose vials and reduced the prices of two smaller doses of the weight-loss drug for self-pay patients. The ...